Wipro and Pandorum Technologies today announced a long-term partnership. Together, the companies will focus on development of technologies that shorten time-to-market and maximise patient outcome during R&D and clinical trials of regenerative medicine. The partnership combines the Artificial Intelligence (AI) capabilities of Wipro Holmes with Pandorum’s expertise in regenerative medicine, the companies said in a joint statement.
The initial focus of collaboration will be on ‘bio-engineered liquid cornea’ and will expand across the product pipeline including lung and liver regenerative tissues, the statement added.
It also mentioned that Wipro Holmes AI-based decision support solution will provide insights on the potential outcomes of specific formulations, apply advanced algorithms to predict and improve the efficacy of therapeutics, and help in clinical study design.
The combined vision of Pandorum and Wipro is to build an AI system that learns from the multi-dimensional data coming out of Pandorum’s R&D pipeline at the cellular, tissue (organoid) and organ levels, and provides actionable insights. Wipro Holmes’ capability in deriving insights from phenotypes, genotypes and clinical progression assessments will complement Pandorum’s capabilities in tissue regeneration and regenerative medicine. Pandorum is on the cusp of entering clinical stage, and the exponential partnership with Wipro, merging Pandorum’s expertise and AI, will unlock the power of regenerative medicine.
“By embracing digital technologies such as AI, lifesciences organisations can accelerate innovation, transform business processes and fuel growth. In lifesciences R&D, AI is particularly valuable to discover new formulations, expedite therapeutic development and bring life-saving therapies to market faster, thereby positively influencing human health. With our domain and AI expertise, we stand ready to enable our health and lifesciences clients to serve their stakeholders better,” said Rajan Kohli, President and Managing Partner, iDEAS, Wipro.
“We’re living in a time of unprecedented progress in biology, data science and machine learning. We are building a framework to converge these three fields, in order to harness the potential of tissue reprogramming to the fullest and address global unmet clinical needs, such as, corneal blindness and liver diseases…….” said Tuhin Bhowmick, co-founder and Chief Executive Officer, Pandorum.